Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 1,543 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Women-Only Clear all
Completed Phase 3 Interventional

Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea

NCT00329459
View directory record Official record
Conditions
Migraine Disorders
Interventions
sumatriptan succinate/naproxen sodium, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
34
States / cities
Mesa, Arizona • Little Rock, Arkansas • Fair Oaks, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Phase 2 Interventional Results available

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

NCT03007979
View directory record Official record
Conditions
Breast Cancer, Breast Carcinoma, Cancer of Breast, Malignant Tumor of Breast
Interventions
Palbociclib, Letrozole, Fulvestrant, Optional research biopsy, Goserelin, Research blood draw, Circulating tumor cell blood draw, Tumor biopsy (optional)
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
St Louis, Missouri • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Physician Attire and Appreciation of Physician Communication in Postpartum Women

NCT03403660
View directory record Official record
Conditions
Patient Satisfaction
Interventions
non White coat
Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 17, 2026, 1:33 AM EDT
Active, not recruiting Phase 1 Interventional

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

NCT05870579
View directory record Official record
Conditions
Breast Cancer
Interventions
[68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Ribociclib, Fulvestrant, Goserelin
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 17, 2026, 1:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Continuation of The Kronos Early Estrogen Prevention Study (KEEPS)

NCT03718494
View directory record Official record
Conditions
Alzheimer Dementia
Interventions
Brain Magnetic Resonance Imaging (MRI), F-18 Florbetapir Positron Emission Tomography (PET) Imaging, F-18 AV-1451 Positron Emission Tomography (PET) Imaging, Neuropsychological Testing
Diagnostic Test · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
49 Years to 72 Years · Female only
Enrollment
299 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
6
States / cities
Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Phase 3 Interventional Results available

MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis

NCT00048061
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
Ibandronate [Bonviva/Boniva], Calcium, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
1,609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
20
States / cities
Irvine, California • Loma Linda, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Not applicable Interventional

Self Biophysical Profile Using a Home Ultrasound Device Proof of Concept

NCT06442358
View directory record Official record
Conditions
Perinatal Care
Interventions
Pulsenmore ES home ultrasound device
Device
Lead sponsor
PulseNmore
Industry
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Potential Drug Interaction Of Bazedoxifene & Premarin In Healthy Postmenopausal Women

NCT00706225
View directory record Official record
Conditions
Postmenopause
Interventions
Bazedoxifene and conjugated estrogens
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2010 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Feasibility of Delphi Screener for Cervical Cytology

NCT00702208
View directory record Official record
Conditions
Cervical Neoplasia
Interventions
Delphi Screener
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
198 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess the Oral Bioavailability of a New ABT-263 Formulation in Healthy Female Subjects

NCT01053520
View directory record Official record
Conditions
Healthy Female Subjects
Interventions
ABT-263
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 9, 2010 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction Study of Clopidogrel 300/75 mg Given Alone or With Omeprazole 80 mg 12 Hours Apart in Healthy Subjects

NCT01129388
View directory record Official record
Conditions
Healthy
Interventions
clopidogrel, Placebo, omeprazole
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117

NCT03443895
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AEF0117 oral capsule, Placebo oral capsule
Drug
Lead sponsor
Aelis Farma
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 17, 2026, 1:33 AM EDT
Recruiting Not applicable Interventional

Promoting Resilience in Women With Breast Cancer (PRISM -MBC)

NCT06855654
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer
Interventions
Promoting Resilience in Women with Breast Cancer (PRISM)
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Birmingham, Alabama • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women

NCT04138056
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 formulation 3, RSVPreF3 formulation 2, Boostrix-ex-US, Boostrix-US, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
509 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
4
States / cities
Miami, Florida • Lenexa, Kansas • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 17, 2026, 1:33 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range

NCT05671653
View directory record Official record
Conditions
Obesity
Interventions
PF-07081532, Semaglutide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 17, 2026, 1:33 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Empowering Mindfulness, Body Respect, and Compassionate Eating Among Women Who Binge Eat During Pregnancy

NCT05581095
View directory record Official record
Conditions
Pregnancy, Binge Eating
Interventions
Mindful Eating Self-Help Program, Mindful Eating Smartphone Application (Am I Hungry? Virtual Coach)
Behavioral
Lead sponsor
University of North Carolina, Charlotte
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 17, 2026, 1:33 AM EDT
Terminated No phase listed Observational

Breath Metabolomics in the Laboring Parturient

NCT04564196
View directory record Official record
Conditions
Labor Onset and Length Abnormalities
Interventions
Breath Sample
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women

NCT07305779
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-380135, Quinidine Gluconate
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 17, 2026, 1:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

MRI Parenchymal Enhancement: A New Marker of Breast Cancer Risk

NCT01649661
View directory record Official record
Conditions
Cancer Free Women
Interventions
questionnaire
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
437 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comprehensive Multi-omics Characterization and Implications of Non-Pharmaceutical Dental Hygiene Product in a Randomized Controlled Large Population Study.

NCT07451782
View directory record Official record
Conditions
Basic Science, Intervention Studies, Biomarker Discovery
Interventions
Oral Lozenges (Tradename pHossident), Water additive (Tradename Protektin)
Dietary Supplement
Lead sponsor
Delta Dental of Minnesota Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
595 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 17, 2026, 1:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Genitourinary and Pharyngeal Pharmacokinetics of Solithromycin

NCT02348424
View directory record Official record
Conditions
Gonorrhoea
Interventions
Solithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Oct 17, 2026, 1:33 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol

NCT00927459
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
PRO-040201, Placebo
Drug
Lead sponsor
Arbutus Biopharma Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 22, 2010 · Synced Oct 17, 2026, 1:33 AM EDT
Recruiting Not applicable Interventional

Women SHINE: Addressing Syndemics and HIV Among Women Through Tech-Based Peer Engagement

NCT05509959
View directory record Official record
Conditions
HIV/AIDS
Interventions
Women SHINE, Control
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 17, 2026, 1:33 AM EDT
Recruiting Phase 4 Interventional

Study Evaluating Safety, Tolerability, and Metabolism of Niraparib

NCT06412120
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Niraparib
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
Fort Lauderdale, Florida • Jacksonville, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 17, 2026, 1:33 AM EDT